Matthew M Y Lee
Overview
Explore the profile of Matthew M Y Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Claggett B, et al.
JAMA Cardiol
. 2024 Sep;
9(11):990-1000.
PMID: 39230885
Importance: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults...
12.
Masri A, Cardoso R, Abraham T, Claggett B, Coats C, Hegde S, et al.
J Am Coll Cardiol
. 2024 Sep;
84(19):1806-1817.
PMID: 39217563
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation,...
13.
Coats C, Masri A, Barriales-Villa R, Abraham T, Brinkley D, Claggett B, et al.
Eur Heart J
. 2024 Sep;
45(42):4464-4478.
PMID: 39217447
Background And Aims: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations...
14.
Lee M, Aimo A, Bayes-Genis A
Eur J Heart Fail
. 2024 Aug;
26(10):2240-2242.
PMID: 39148229
No abstract available.
15.
Lee M, Petrie M, Cleland J, Donnelly P, Francis M, Hannah A, et al.
Eur J Heart Fail
. 2024 Jul;
26(10):2293-2295.
PMID: 39078467
No abstract available.
16.
Coats C, Masri A, Nassif M, Barriales-Villa R, Arad M, Cardim N, et al.
J Am Heart Assoc
. 2024 Jul;
13(15):e035993.
PMID: 39056349
Background: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM...
17.
Shen L, Lee M, Jhund P, Granger C, Anand I, Maggioni A, et al.
JAMA
. 2024 May;
331(24):2094-2104.
PMID: 38809561
Importance: Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF). Objective: To determine whether...
18.
Sattar N, Lee M, McGuire D
Nat Med
. 2024 May;
30(7):1830-1831.
PMID: 38796654
No abstract available.
19.
Curtain J, Talebi A, McIntosh A, McConnachie A, ODonnell J, Welsh P, et al.
Eur J Heart Fail
. 2024 May;
26(6):1383-1392.
PMID: 38741283
Aims: We examined the effectiveness of a novel cardiopulmonary management wearable sensor (worn for less than 5 mins) at measuring congestion and correlated the device findings with established clinical measures...
20.
Maron M, Masri A, Nassif M, Barriales-Villa R, Arad M, Cardim N, et al.
N Engl J Med
. 2024 May;
390(20):1849-1861.
PMID: 38739079
Background: One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract...